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a  b  s  t  r  a  c  t
Background:  microRNAs  have  recently  been  identiﬁed  as  powerful  biomarkers  of  human  disease.  Reliable
polymerase  chain  reaction  (PCR)-based  quantiﬁcation  of  nucleic  acids  in clinical  samples  contaminated
with  polymerase  inhibitor  heparin  requires  deheparinization.  However,  the  effects  of  deheparinization
procedure  on  quantiﬁcation  of nucleic  acids  remain  largely  unknown.  The  aim of  this  study  was  to deter-
mine  whether  the  deheparinization  procedure  completely  eliminates  the  inhibition  of ampliﬁcation,
while  maintaining  RNA  integrity  and  technical  variability  of  the  measured  microRNA  levels.
Methods:  Heparinized  plasma  from  9 patients  undergoing  coronary  artery  bypass  grafting  (CABG)  and  the
heparin-free  plasma  from  58  rats  were  spiked  with  a synthetic  RNA  oligonucleotide  and  total  RNA  was
extracted.  The  RNA  solutions  were  then  treated  with  heparinase  I to remove  contaminating  heparin  prior
to reverse  transcription.  Levels  of synthetic  spike-in  RNA  oligonucleotide,  as  well as endogenous  hsa-miR-
1-3p  and  hsa-miR-208a-3p,  were  measured  using  quantitative  reverse  transcription  PCR  (RT-qPCR).  The
ampliﬁcation  efﬁciency  and  presence  of  inhibitors  in  individual  samples  were  directly  determined  using
calibration  curves.
Results: In contrast  to  RNA  samples  from  rat plasma,  RNA  samples  derived  from  the  CABG  patient  plasma
contained  inhibitors,  which  were  completely  eliminated  by treatment  with  heparinase.  The  procedure
caused  a decrease  in  the  amount  of detected  RNA;  however,  the  technical  variability  of  the  measured
targets  did  not  change,  allowing  for the  quantiﬁcation  of circulating  endogenous  hsa-miR-1-3p  and  hsa-
miR-208a-3p  in the plasma  of  CABG  patients.
Conclusions:  The  heparinase  treatment  procedure  enables  utilization  of RT-qPCR  for  reliable  microRNA
quantiﬁcation  in heparinized  plasma.
© 2016  The  Authors.  Published  by  Elsevier  GmbH.  This  is an  open  access  article  under  the CC
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1. Introduction
Heparin, a commonly used anticoagulant, seriously complicates
polymerase chain reaction (PCR)-based analysis of nucleic acids in
clinical samples, since it inhibits both reverse transcription (RT)
and PCR ampliﬁcation steps. The routine methods of RNA isolation,
including column puriﬁcation, do not remove heparin from RNA
samples [1,2]. Currently, the only effective and universal approach
to remove heparin is to treat RNA samples with heparinase [2].
The effects of treating RNA with heparinase for PCR-based
studies have been estimated by several approaches that include
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valuation of the electrophoretic band intensity of the PCR prod-
ct [3], calculation of the proportion of target-positive samples
4], and monitoring changes in values of quantiﬁcation cycle (Cq)
5–8]. These approaches are only sufﬁcient to check the suitabil-
ty of heparinase-treated samples for qualitative analysis of target
ucleic acids because they measure reduced inhibition of the RT
nd PCR assays but do not prove complete elimination of heparin
rom the sample.
Reverse transcription quantitative PCR (RT-qPCR) is a conven-
ional method for quantitative analysis of absolute and relative
evels of target RNAs [9]. However, there are problems regarding
he reliability of RT-qPCR analyses of RNA from heparinase-treated
amples due to the lack of data on several critical parame-
ers of deheparinized samples. These parameters are as follows:
i) efﬁciency of enzymatic reactions, which directly inﬂuences
oth accuracy and precision of RT-qPCR-based quantiﬁcation, (ii)
ariability of RNA levels after additional pipetting steps, which
nﬂuence precision, and (iii) changes in RNA integrity, which
mpede comparison of deheparinized and heparin-free untreated
amples, as well as detection of low copy number transcripts. In the
resent study, we sought to characterize these parameters after
eparinase treatment to determine whether the procedure com-
letely removed the heparin, thus ensuring equal efﬁciencies in
ownstream enzymatic reactions, and whether the variability of
easured RNA levels and integrity of the target RNA was  preserved.
In the present study, RNA samples from rat plasma were used
s a control to assess variability of the measured Cq in the absence
f both inhibition and heparinase treatment. The inhibitory action
f heparin in RNA samples from the plasma of coronary artery
ypass grafting (CABG) patients collected at different timepoints
uring surgery was analyzed and the effect of heparinase treatment
n the efﬁciency of enzymatic reactions was determined. RT-qPCR
nalysis of either heparinase-treated or untreated aliquots of tar-
et RNA aqueous solutions allowed us to determine the effect of
eparinase treatment on RNA integrity and Cq variability. Finally,
e tested whether treatment with heparinase allows for the detec-
ion of endogenous high- and low-abundance microRNAs in plasma
amples of CABG patients. Hsa-miR-1-3p was selected as one of the
ost abundance microRNAs in both skeletal and cardiac muscles
nd hsa-miR-208a-3p was selected as relatively low-abundance
ardiospeciﬁc microRNA [10]. Both microRNAs are known to be
pregulated in the plasma of patients after acute myocardial infarc-
ion [11].
. Materials and methods
.1. Study cohort and blood sampling
Written informed consent was obtained from all patients under-
oing CABG. The study has been approved by the local Ethics
ommittee and conforms to the principles outlined in the Declara-
ion of Helsinki. Patients included in this study (n = 9) had cardiac
roponin I levels less than 0.011 ng/mL before surgery and greater
han 1.249 ng/mL within 120 min  after aortic declamping. Patients
eceived bolus dose of unfractionated heparin (B. Braun Medical
nc., Melsungen, Germany) approximately 30 min  after thoraco-
omy. Some patients received maintenance dose of heparin during
ardiopulmonary bypass. Heparin doses were adjusted to maintain
ctivated clotting time during cardiopulmonary bypass between
00 and 450 s. The average total heparin dose was 312 IU/kg (range
61–450 IU/kg). Whole blood samples were collected in EDTA tubes
t the following time points: 40 min  before heparin bolus dose
dministration (time point 1 (TP1)) as well as 20 min  (TP2), 140 min
TP3), and 260 min  (TP4) after heparin bolus dose administra-
ion (Supplementary Fig. 1). Samples at TP1, TP4 and TP2, TP3n and Quantiﬁcation 8 (2016) 9–14
were drawn from the peripheral vein and from the coronary sinus,
respectively. Clinical data and information on exact heparin doses
are provided in the Supplementary Table 1.
2.2. Animals and blood sampling
Fifty eight male Wistar rats (weight 300–350 g) were enrolled in
the study. Whole blood was collected in EDTA tubes from the aorta
immediately after thoracotomy (control group, n = 10) or 120 min
after thoracotomy (ischemia-reperfusion group, n = 48). All pro-
cedures were performed in accordance with the Guide for the
Care and Use of Laboratory Animals (NIH publication No. 85–23,
revised 1996), European Convention for the Protection of Verte-
brate Animals used for Experimental and Other Scientiﬁc Purposes.
The study protocol was approved by the local Ethics Committee.
The details on animal care and surgery procedures used to induce
myocardial ischemia-reperfusion are provided in the Supplemen-
tary methods.
2.3. Plasma preparation
Human and rat whole blood samples were stored at 4 ◦C for
a maximum of 30 min  after collection. Plasma was  isolated using
double centrifugation at 1600g for 10 min  at 4 ◦C. Samples were
aliquoted, snap frozed in liquid nitrogen and stored at −80 ◦C.
2.4. Isolation of total RNA
Total RNA, including small RNA species, was  isolated from
200 L of plasma using 600 L of TRIzol LS reagent (Life Tech-
nologies Co., Carlsbad, USA) that was pre-mixed with 1 g of
Escherichia coli tRNA (Sigma-Aldrich Co., Missouri, USA) and
108 molecules of the synthetic RNA oligonucleotide synth-cel-
miR-39 (Syntol, Moscow, Russia), which is identical to mature
Caenorhabditis elegans microRNA cel-miR-39-3p (miRBase acces-
sion: MIMAT0000010). RNA was  isolated according to the
manufacturer’s recommendations. The RNA pellet was  air dried,
and dissolved in 10 L of RNase-free water and stored at −80 ◦C. The
details on RNA integrity analysis are provided in the Supplementary
methods and Supplementary Fig. 2.
2.5. Heparin elimination procedure
Heparin was eliminated from RNA isolated from CABG patient
plasma samples using the protocol described by Izraeli et al. [2] with
some modiﬁcations as described in the Supplementary methods. To
test the effect of heparinase treatment on Cq variability and RNA
integrity, we compared the ampliﬁcation of synth-cel-miR-39 from
heparinase-treated with that of a control synth-cel-miR-39 water
solution. The details of these methodologies are provided in the
Supplementary methods.
2.6. RT-qPCR quantiﬁcation
Target RNAs were detected using hydrolysis probe-based Taq-
Man  MicroRNA Assays. Reverse transcription was performed using
TaqMan MicroRNA Reverse Transcription Kit (Life Technologies),
ampliﬁcation was performed using TaqMan Universal PCR Master
Mix  (Life Technologies) according to the manufacturer’s recom-
mendations. The details of these assays are provided in the
Supplementary.2.7. Data analysis
The Shapiro-Wilk test was used to check the normality of
data. The Student’s t-test (for normally distributed data and
























































Fig. 1. RNA samples isolated from CABG patient plasma contain polymerase
inhibitors, which are sensitive to heparinase treatment.
Standard curves were generated using 10-fold serial dilutions of RNA samples iso-
lated from CABG patient plasma collected at TP1 (A) and TP2 (B) or from rat plasma
(C).  Y-intercepts (Y-int), coefﬁcients of determination (R2) for linear regression mod-
els, slopes and reactions efﬁciencies (Eff) were determined and are indicated. The
black and open squares represent data points within and outside the linear range of
dependence of Cq on the logarithm of the synth-cel-miR-39 concentration, respec-
tively. Crosses represent data points, which Cq values were arbitrary assigned to 40,
since corresponding sample dilutions show no reporter ﬂuorescence until cycle 40.
The  dotted lines indicate 95% conﬁdence band of the best ﬁt lines.
(D) Scatter-plots show the variability of Cq values obtained after synth-cel-miR-
39  ampliﬁcation from RNA samples isolated from CABG patient plasma collected
at  TP1 (n = 9) and TP2 (n = 9). RNA samples were either untreated or treated withK. Kondratov et al. / Biomolecular De
ndependent samples) or nonparametric Wilcoxon signed-rank test
for non-normally distributed data and paired samples) were used
o assess the differences between the means of two groups. The
-test was used to compare Cq variances between two  groups.
wo-sided P values less than 0.05 were considered statistically sig-
iﬁcant. R-package (version 2.12.0) was used to perform statistical
nalysis and visualizations.
. Results
.1. Efﬁciency of RT-qPCR enzymatic reactions can be analyzed by
mpliﬁcation of spike- in synth-cel-miR-39 from serially diluted
ndividual RNA samples
In the present study, we analyzed calibration curves to directly
ssess inhibition and efﬁciency of RT-qPCR enzymatic reactions.
n a validation experiment, 10-fold serial dilutions of synth-cel-
iR-39 in water were used as templates. The dependence of Cq
n the logarithm of the synth-cel-miR-39 concentration was linear
R2 = 0.996, efﬁciency = 91%) throughout the entire range of concen-
rations tested (104–109 molecules in 5 L reverse transcription
eaction) (Supplementary Fig. 3A). This range includes a value
f 0.83 × 107 molecules in a 5 L reverse transcription reaction,
hich is the maximum concentration of synth-cel-miR-39 oligonu-
leotide that can be achieved in RNA samples isolated from plasma
s ee RT-qPCR quantiﬁcation section of Supplementary methods
or detailed calculations). Thus, the set of reagents used for RT and
CR ampliﬁcation of synth-cel-miR-39 has sufﬁcient sensitivity and
apacity for accurate detection of levels of this spike-in oligonu-
leotide in RNA samples from patient plasma and therefore it can
e used to control for the presence of inhibitors by monitoring the
eviations from linearity of synth-cel-miR-39 calibration curves at
igh template concentrations.
.2. RNA samples from CABG patients plasma collected before,
uring, and after surgery contain various amounts of RT-qPCR
nhibitors
No inhibition of the RT-qPCR enzymatic reaction was observed
hen synth-cel-miR-39 was ampliﬁed from serial dilutions of RNA
amples obtained from rat plasma (Fig. 1C). In contrast, calibration
urves for RNA samples from CABG patient plasma were non-linear.
he linear relationship between Cq and the logarithm of synth-cel-
iR-39 concentration was restored when RNA samples from CABG
atient were diluted from 10- to 1000-fold (Figs. 1A and B; 2).
Contamination of RNA samples from CABG patient plasma
ith various amounts of RT-qPCR inhibitors was  conﬁrmed by
bservation of considerable Cq variability (SD = 2.97) when synth-
el-miR-39 was ampliﬁed from undiluted RNA from plasma
amples collected before surgery (TP1) (Fig. 1D) and the absence of
ynth-cel-miR-39 ampliﬁcation from undiluted RNA from plasma
amples collected 20 min  after administration of the bolus heparin
ose (TP2) (data not shown).
.3. Heparinase treatment of RNA samples from CABG patient
lasma completely eliminates inhibition of RT-qPCR enzymatic
eactions
Since heparin is a known inhibitor of both the RT and PCR
eactions, we tested whether heparinase treatment would alter
he efﬁcacy of the enzymatic reaction. We  found that heparinase
reatment of RNA samples prior to reverse transcription decreased
q variability in TP1 samples (SD = 0.35) and enabled detection
f synth-cel-miR-39 in TP2 samples (SD = 0.48) (Fig. 1D), suggest-
ng that heparin did indeed inhibit target detection via RT-qPCR.
nalysis of data variance showed statistically signiﬁcant differenceheparinase prior to reverse transcription as indicated. The horizontal lines show
the median Cq values. SD represent standard deviation, Cq represent difference
between the highest and the lowest Cqs for each group, P value is for Student’s t-test.
between Cq variances of TP1 samples before and after treatment (F-
test, P = 2 × 10−6). There were no statistically signiﬁcant differences
between Cq variances (F-test, P = 0.382) and Cq values (Student’s
t-test, P = 0.33) of TP1 and TP2 samples after treatment.
To evaluate the extent of inhibitor removal by heparinase treat-
ment, synth-cel-miR-39 was ampliﬁed from serial dilutions of
several RNA samples isolated from CABG patients, which were
either treated or untreated with heparinase. Analysis of the result-
ing calibration curves demonstrated that, despite a variable degree
of inhibition at different time points in the untreated samples, addi-
tion of heparinase resulted in the complete elimination of inhibition
and equal efﬁciency of the enzymatic ampliﬁcation reaction in all
samples (Fig. 2).
3.4. Heparinase treatment reduced the target RNA yield but had
no effect on Cq variability
The heparin elimination procedure includes additional sample
handling steps and requires treatment of RNA for an extra 3 h at
25 ◦C with heparinase. To assess the cumulative impact of this extra
handling on Cq variability and RNA integrity, we compared synth-
cel-miR-39 ampliﬁcation from three groups of aliquots of aqueous
synth-cel-miR-39 solutions. The ﬁrst group of aliquots contained
no heparin and was  not treated with heparinase (control), the
second contained no heparin but was treated with heparinase (hep-
arinase), and the third group of aliquots was  supplemented with
heparin and was treated with heparinase (heparinase + heparin).
Without heparinase treatment, the concentration of heparin in
the reverse transcription reactions with RNA from the third
group of aliquots would be similar to that with RNA from CABG
patients plasma collected a short time after administration of bolus
dose of heparin (see Heparin elimination procedure section of
12 K. Kondratov et al. / Biomolecular Detection and Quantiﬁcation 8 (2016) 9–14
Fig. 2. Heparinase treatment of RNA samples from CABG patient plasma completely abolished inhibition of PCR ampliﬁcation.
Calibration curves generated after synth-cel-miR-39 ampliﬁcation from 10-fold serial dilutions of RNA samples isolated from plasma of selected CABG patients (c35, d64,
m26),  collected at indicated time points. RNA samples were either untreated (−) or treated (+heparinase) with heparinase prior to dilution and reverse transcription. Y-
i lopes






























tntercepts (Y-int), coefﬁcients of determination (R2) for linear regression models, s
pen  squares represent data points within and outside the linear range of dependen
ines  indicate 95% conﬁdence band of the best ﬁt lines.
upplementary methods for detailed calculations). Heparinase
reatment of the aliquots led to a 5-fold decrease in measured levels
f synth-cel-miR-39 (Student’s t-test, P = 0.002) and did not signiﬁ-
antly change the Cq variance as compared to the non-heparinized
ntreated aliquots (F-test, P = 0.519). The presence of heparin in
amples before heparinase treatment did not inﬂuence the mea-
ured Cq values or their variances because both parameters did
ot differ between heparin-free heparinase-treated and heparin-
ontaining heparinase-treated groups (Student’s t-test, P = 0.271;
-test, P = 0.958) (Fig. 3A). The absence of signiﬁcant inﬂuence of
eparinase treatment on Cq variance was conﬁrmed by comparison
f the ampliﬁcation of spike-in synth-cell-miR-39 in heparinase-
reated RNA samples from CABG patients plasma (n = 36) and
ntreated RNA samples from non-heparinized rat plasma (n = 58)
F-test, P = 0.96) (Fig. 3B and C). Coefﬁcients of variation for the con-
entration of synth-cel-miR-39 were 47.8% in heparinase treated
ABG samples and 48% in rat samples. In an additional experi-
ent we analyze inﬂuence of heparinese treatment on the integrity
f four different microRNAs (synth-cel-miR-39, synth-hsa-miR-
6, synth-hsa-miR-21 and synth-hsa-miR-208a) at two  different
oncentrations. Results of this experiment (Supplementary Fig. 4)
emonstrate that (i) heparinase treatment has no effect on Cq
ariability of all investigated targets, both at high and at low con-
entration, (ii) heparinase treatment causes different degree of
egradation of different targets (3- to 4-fold for synth-cel-miR-39,
-fold for synth-hsa-miR-16, 6- to 6.5-fold for synth-hsa-miR-21
nd 1.5- to 1.6-fold for synth-hsa-miR-208a). So deheparinisation
rocedure introduce bias in gene expression data due to degrada-
ion, which is non-reproducible among genes. and reactions efﬁciencies (Eff) were determined and are indicated. The black and
q on the logarithm of the synth-cel-miR-39 concentration, respectively. The dotted
3.5. Heparinase treatment enables quantiﬁcation of both high-
and low- abundance muscle-enriched microRNAs in CABG patient
samples
Next, we determined whether heparinase-treated RNA isolated
from CABG patient plasma is suitable for detection of endogenous
high- and low-abundance circulating microRNAs. We  used RT-qPCR
to measure the absolute levels of endogenous hsa-miR-1-3p and
hsa-miR-208a-3p. The highly-abundance hsa-miR-1-3p was reli-
ably detected in all TP1 and TP4 plasma samples. However, levels
of low-abundance hsa-miR-208a-3p were below the lower limit
of assay linearity in two  TP1 samples and two TP4 samples. In the
remaining seven TP1 samples no ampliﬁcation of hsa-miR-208a-3p
was detected. We  assigned these samples values to the lower limit
of assay linearity in order to include them in the study. Analysis
of these data revealed statistically signiﬁcant upregulation in both
hsa-miR-1-3p (Wilcoxon signed-rank test, P = 0.008) and hsa-miR-
208a-3p (Wilcoxon signed-rank test, P = 0.023) in TP4 samples as
compared to the TP1 samples (Fig. 4).
4. Discussion
To our knowledge, this is the ﬁrst study designed to use cali-
bration curves to investigate the presence of inhibitors or RT-qPCR
enzymatic reactions in RNA samples isolated from the plasma of
CABG patients and to analyze the inﬂuence of the deheparinization
procedure on circulating microRNAs quantiﬁcation by RT-qPCR.
Heparin is routinely administered as anticoagulant during car-
diovascular interventions, with average bolus dose ranging from
60 IU/kg for cardiac catheterization procedures to 310 IU/kg for
K. Kondratov et al. / Biomolecular Detectio
Fig. 3. Heparinase treatment does not increase variability of measured Cq, but does
compromise RNA integrity.
(A) Synth-cel-miR-39 was  ampliﬁed from three groups of aliquots of aqueous
synthetic oligonucleotide solution. The aliquot groups were as follows: heparin-
free with no heparinase treatment (control, n = 5), heparin-free treated with
heparinase (heparinase, n = 5), or heparin-containing treated with heparinase (hep-
arinase + heparin, n = 5). Synth-cel-miR-39 was ampliﬁed from RNA samples isolated
from (B) CABG patient plasma, treated with heparinase prior to reverse transcription
(n = 36) or (C) non-heparinized rat plasma (n = 58). Data shown in panels (B) and (C)












































starting PCR-based analysis of nucleic acids from all types of clin-
ical samples that can potentially contain heparin. The calibration
curve method is a relatively simple and accurate approach to the
Fig. 4. Heparinase treatment enables quantiﬁcation of endogenous microRNAs inent individual samples, horizontal lines show the median Cq values. SD represent
tandard deviation, Cq represent difference between the highest and the lowest
qs for each group, P values are for Student’s t-test.
ABG [12,13]. Recent studies have shown that, even in cardiac
atheterization patients, within 1 h of dosing, the heparin blood
oncentration is high enough to interfere with the quantiﬁcation
f circulating microRNA by RT-qPCR methods [6,7]. Effect of par-
ial inhibition can be adjusted by normalization of individual Cqs
ith the average Cq of multiple targets [7]. Despite these observa-
ions, numerous recent publications report the levels of circulating
icroRNAs in patients undergoing cardiovascular interventions,
ncluding transcoronary ablation of septal hypertrophy [14], elec-
ive mitral valve surgery [15], and CABG [16,17], and it is unclear
hether the effects of heparin were considered in these studies.
oreover, in response to the paper by Libertau et al. [14], Mayr
t al. argued that even the traces of heparin can interfere with the
esults of microRNA measurements in cardiovascular patients [18].
In the present study, we used calibration curves to directly
etermine the ampliﬁcation efﬁciency of RNA targets. Using this
ethod, we were able to detect the presence of inhibitors and to
onitor efﬁcacy of inhibitor removal after treatment with hep-
rinase. Moreover, we used the calibration curves to estimate the
mount of inhibitor in particular samples by determining the dilu-
ion factor required to sufﬁciently restore a linear relationship
etween Cq and the logarithm of template concentration. We  found
hat samples collected 20 min  after administration of bolus heparin
ose (TP2) contained the highest levels of heparin, since ampliﬁ-
ation of synth-cel-miR-39 failed in all undiluted TP2 samples, but
ot in undiluted TP1, TP3 and TP4 samples. TP3 samples should
e diluted from 100- to 1000-fold, whereas TP4 samples should
e diluted only from 10- to 100-fold (Fig. 2) suggesting that the
evel of heparin in samples rapidly declines after TP2. This tem-
oral inhibitory effect can be explained by the short half-life of
nfractionated heparin in circulation and is in agreement with an
arlier study that reported the disappearance of heparin inhibition
etween 4 h and 6 h post administration in plasma samples of car-
iac catheterization patients [7]. Unexpectedly, we  observed a huge
ange of measured Cq values (Cq = 7.9, Fig. 1D) in plasma samples
rom CABG patients collected before surgery (TP1) which indicates
he presence of differing amounts of heparin in these samples, pos-
ibly from heparin-containing rinse solution left in catheters before
hey were used for collection of blood samples.
RT-qPCR-based analysis of spike-in synth-cel-miR-39 in plasma
rom CABG patients clearly showed that samples collected before as
ell as several minutes to hours after heparin administration hadn and Quantiﬁcation 8 (2016) 9–14 13
very different levels of enzymatic assay inhibition. Therefore, it is of
great importance to use the heparin elimination protocol to com-
pletely remove the heparin regardless of the initial levels in order
to avoid inaccurate interpretation of target microRNA expression.
Several papers reported heparinase treatment of plasma sam-
ples as a method to remove heparin [4,19]. However, it is important
to note that heparin in plasma is partially protected from degra-
dation due to interaction with proteins. Therefore, to avoid the
protective effect of proteins and also to reduce the volume of enzy-
matic reaction to consume less heparinase, we treated isolated
RNA in the presence of an RNase inhibitor, as described by Izraeli
et al. [2]. Moreover, to guarantee complete digestion of heparin,
we extended the duration of heparinase treatment from 2 h to 3 h.
Analysis of calibration curves demonstrated that, despite initial dif-
ferences in the degree of inhibition, treatment with heparinase
ensured complete removal of the inhibitor. Our data comparing
control and heparinase-treated samples revealed that the addi-
tional sample handling performed during the heparinase treatment
caused a 1.5- to 6.5-fold decrease in the measured target levels
but did not increase variability of Cq. These results indicate that
heparinase treatment did not reduce the precision of RT-qPCR
based assay, but moderately decreased its sensitivity. However,
we demonstrated that the heparinase treatment protocol allows
for the detection of endogenous muscle-enriched high-abundance
hsa-miR-1-3p in TP1 and TP4 samples as well as low-abundance
hsa-miR-208a-3p in TP4 samples. Both microRNAs were found to
be elevated after surgery. The most likely reason for the decrease
of the measured target levels after heparinase treatment is RNA
degradation by RNases, which might be present in the heparinase
preparation. To minimize the loss of RNA one can try to reduce the
time of deheparinisation and/or to increase the concentration of
RNase inhibitors. However, it is important to verify whether these
changes affect the completeness of heparin removal.
In addition to blood samples collected in heparinized tubes
or samples collected from patients receiving heparin regimens,
there are other ways in which samples can become contaminated
with heparin. For example, our study revealed that patient plasma
samples collected in EDTA tubes before systemic heparin admin-
istration were contaminated with heparin, probably originating
from catheter rinse solutions. Moreover, the spectrum of clinical
specimens containing heparin becomes broader if we take into
account that injected heparin is partly excreted in urine [20] and
retained in organs perfused with heparinized buffers [3]. Therefore,
it is recommended to evaluate the presence of inhibitors beforeplasma samples from CABG patients.
Plots show absolute levels of hsa-miR-1-3p (A) and hsa-miR-208a-3p (B) in 1 mL
of  plasma samples collected before (TP1, n = 9) and after (TP4, n = 9) CABG surgery.
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valuation of ampliﬁcation efﬁciency and presence of inhibitors.
o overcome inhibition, samples can be diluted or treated with
eparinase depending on the abundance of the target nucleic acid
nd the dose and timing of heparin administration. We  believe that
mplementing this method will ensure that RT-qPCR can be used to
eliably quantify nucleic acids in clinical samples.
In conclusion, this study provides evidence that the heparinase
reatment of RNA samples from CABG patient plasma completely
eversed heparin-induced inhibition of downstream enzymatic
ssays and caused different (1.5- to 6.5-fold) reduction of measured
NA levels for different targets without signiﬁcant changes in Cq
ariability.
onﬂict of interest
The authors declare no conﬂict of interests.
cknowledgment
The work was supported by grant from the RFBR (project 14-04-
1833).
ppendix A. Supplementary data
Supplementary data associated with this article can be found, in
he online version, at http://dx.doi.org/10.1016/j.bdq.2016.03.001.
eferences
[1] E. Beutler, T. Gelbart, W.  Kuhl, Interference of heparin with the polymerase
chain reaction, Biotechniques 9 (1990) 166.
[2] S. Izraeli, C. Pﬂeiderer, T. Lion, Detection of gene expression by PCR
ampliﬁcation of RNA derived from frozen heparinized whole blood, Nucleic
Acids Res. 19 (1991) 6051.[3] X. Bai, S. Fischer, S. Keshavjee, et al., Heparin interference with reverse
transcriptase polymerase chain reaction of RNA extracted from lungs after
ischemia-reperfusion, Transpl. Int. 13 (2000) 146–150.
[4] H. Imai, O. Yamada, S. Morita, et al., Detection of HIV-1 RNA in heparinized
plasma of HIV-1 seropositive individuals, J. Virol. Methods 36 (1992) 181–184.
[
[n and Quantiﬁcation 8 (2016) 9–14
[5] M.  Johnson, C. Navanukraw, A. Grazul-Bilska, et al., Heparinase treatment of
RNA before quantitative real-time RT-PCR, Biotechniques 35 (2003)
1140–1144.
[6] J. Boeckel, C. Thome, D. Leistner, et al., Heparin selectively affects the
quantiﬁcation of microRNAs in human blood samples, Clin. Chem. 59 (2013)
1125–1127, http://dx.doi.org/10.1373/clinchem.2012.199505.
[7]  D. Kaudewitz, R. Lee, P. Willeit, et al., Impact of intravenous heparin on
quantiﬁcation of circulating microRNAs in patients with coronary artery
disease, Thromb. Haemost. 110 (2013) 609–615, http://dx.doi.org/10.1160/
TH13-05-0368.
[8] J. Plieskatt, Y. Feng, G. Rinaldi, et al., Circumventing qPCR inhibition to amplify
miRNAs in plasma, Biomark. Res. 2 (2014) 13, http://dx.doi.org/10.1186/
2050-7771-2-13.
[9] C. Pritchard, H. Cheng, M.  Tewari, MicroRNA proﬁling: approaches and
considerations, Nat. Rev. Genet. 13 (2012) 358–369, http://dx.doi.org/10.
1038/nrg3198.
10] S. Kuchen, W.  Resch, A. Yamane, et al., Regulation of microRNA expression
and abundance during lymphopoiesis, Immunity 32 (2010) 828–839, http://
dx.doi.org/10.1016/j.immuni.2010.05.009.
11] G. Wang, J. Zhu, J. Zhang, et al., Circulating microRNA: a novel potential
biomarker for early diagnosis of acute myocardial infarction in humans, Eur.
Heart J. 31 (2010) 659–666, http://dx.doi.org/10.1093/eurheartj/ehq013.
12] D. Doty, H. Knott, J. Hoyt, et al., Heparin dose for accurate anticoagulation in
cardiac surgery, J. Cardiovasc. Surg. 20 (1979) 597–604.
13] G. Niccoli, A. Banning, Heparin dose during percutaneous coronary
intervention: how low dare we go? Heart 88 (2002) 331–334.
14] C. Liebetrau, H. Mollmann, O. Dorr, et al., Release kinetics of circulating
muscle-enriched microRNAs in patients undergoing transcoronary ablation of
septal hypertrophy, J. Am.  Coll. Cardiol. 62 (2013) 992–998, http://dx.doi.org/
10.1016/j.jacc.2013.05.025.
15] X. Zhou, A. Mao, X. Wang, et al., Urine and serum microRNA-1 as novel
biomarkers for myocardial injury in open-heart surgeries with
cardiopulmonary bypass, PLoS One 8 (2013) e62245, http://dx.doi.org/10.
1371/journal.pone.0062245.
16] O. Gidlof, J. Smith, K. Miyazu, et al., Circulating cardio-enriched microRNAs are
associated with long-term prognosis following myocardial infarction, BMC
Cardiovasc. Disord. 13 (2013) 12, http://dx.doi.org/10.1186/1471-2261-13-12.
17] Y. Yao, J. Du, X. Cao, et al., Plasma levels of microRNA-499 provide an early
indication of perioperative myocardial infarction in coronary artery bypass
graft patients, PLoS One 9 (2014) e104618, http://dx.doi.org/10.1371/journal.
pone.0104618.
18] M.  Mayr, R. Lee, D. Kaudewitz, et al., Effects of heparin on temporal microRNA
proﬁles, J. Am.  Coll. Cardiol. 63 (2014) 940–941, http://dx.doi.org/10.1016/j.
jacc.2013.07.118.19] D. Kim, S. Linnstaedt, J. Palma, et al., Plasma components affect accuracy of
circulating cancer-related microRNA quantitation, J. Mol. Diagn. 14 (2012)
71–80.
20] A. Copley, The excretion of injected heparin in the urine of mice and dogs,
Science 93 (1941) 478–479, http://dx.doi.org/10.1016/j.jmoldx.2011.09.002.
